NASDAQ:ZNTL Zentalis Pharmaceuticals Q3 2026 Earnings Results & Report $1.89 +0.09 (+5.00%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.53%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zentalis Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.34 versus the -$0.5423 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call7:00 AM ET Zentalis Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.5423Beat/MissBeat by +$0.2023One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersZentalis Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zentalis Pharmaceuticals Q3 2026 Earnings FAQ Did Zentalis Pharmaceuticals beat earnings estimates for Q3 2026? Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported earnings of -$0.34 per share for Q3 2026, beating the consensus estimate of -$0.5423. The report was announced on Monday, November 9, 2026. Zentalis Pharmaceuticals Earnings HeadlinesZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesNovember 9 at 4:05 PM | globenewswire.comZentalis Pharmaceuticals (ZNTL) Expected to Post Quarterly Earnings on TuesdayNovember 9 at 1:56 AM | americanbankingnews.comHas The AI Bubble Popped?A recent sell-off wiped $2.3 trillion off the Nasdaq 100 in a single day, leaving Wall Street split on whether the AI trade is dead. Porter Stansberry says money is already migrating out of tech and into a forgotten sector that one major Wall Street bank upgraded while downgrading tech. He argues it's tied to the AI build-out and could produce the next Magnificent 7. His new broadcast covers which stocks he'd consider selling, where he believes the money is heading, and a large-cap name he believes could 5x over five years.November 11 at 1:00 AM | Porter & Company (Ad)Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 2, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Median Overall Survival Data In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer From DENALI Part 1bOctober 24, 2026 | marketscreener.comMSee More Zentalis Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email. Email Address About Zentalis PharmaceuticalsZentalis Pharmaceuticals (NASDAQ:ZNTL) (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response. The company has evaluated azenosertib in multiple cancer types and continues to investigate its potential as a treatment for solid tumors and hematologic malignancies. Zentalis has also developed additional oncology candidates aimed at targets such as BCL-2 and other mechanisms relevant to cancer biology. The company was established in 2014 and is headquartered in San Diego, California. Its development programs are conducted through clinical research and collaborations with medical institutions and other research organizations. Zentalis is led by Kimberly L. Blackwell, M.D., who serves as chief executive officer and has experience in oncology drug development and commercial strategy.View Zentalis Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
